Log in

View Full Version : Reports and Research

  1. Prograf toxic to Kidneys (1 replies)
  2. FDA Rejects Astellas Immune System Drug Petition (0 replies)
  3. Roche transplant drug gets anemia warning (0 replies)
  4. 8 Promising Hepatitis C Drugs (0 replies)
  5. Transplant livers may be offered to larger region (0 replies)
  6. Fecal transplant no laughing matter (0 replies)
  7. Baffling the body into accepting transplants (0 replies)
  8. Expert Food Tips for Chronic Hepatitis C: Part 1 (0 replies)
  9. Hepatitis C Vaccine on the horizon (0 replies)
  10. Another Article on articial livers (0 replies)
  11. FDA Testing Artifical Liver (0 replies)
  12. Organ Transplantation Policies and Policy Reforms Sept. 2006 (0 replies)
  13. FDA stresses birth defect risks with Roche drug (0 replies)
  14. Liver Biopsy (1 replies)
  15. ERCP (Endoscopic Retrograde Cholangiopancreatography) (0 replies)
  16. What You Need to Know about the Transjugular Intrahepatic Portosystemic Shunt (TIPS) (0 replies)
  17. High-protein diets: Safe if you have kidney or liver disease? (0 replies)
  18. Lots of Clinical Trials on Liver Disease (0 replies)
  19. Congenital cholestatic syndromes: What happens when children grow up? (0 replies)
  20. Elevation of serum stem-cell factor in postoperative biliary atresia (0 replies)
  21. Can biliary atresia be diagnosed by ultrasonography alone? (0 replies)
  22. The evidence of maternal microchimerism in biliary atresia using fluorescent in situ (0 replies)
  23. High-dose steroids do not improve early outcome in biliary atresia (0 replies)
  24. Management of adult biliary atresia patients: should hard work and pregnancy be disco (0 replies)
  25. Excerpt from Biliary Atresia (0 replies)
  26. Paediatric liver transplantation in New Zealand: the first 5 years. (0 replies)
  27. Histological recurrence of autoimmune liver diseases after living-donor liver transpl (0 replies)
  28. Analysis of Model for End-Stage Liver Disease (MELD) Score in a Liver Transplantation (0 replies)
  29. Early stage of biliary atresia is associated with significant changes in 8-hydroxydeo (0 replies)
  30. Hyaluronic acid: Additional biochemical marker in the diagnosis of biliary atresia. (0 replies)
  31. Hepatic Arterial Diameter Measured with US: Adjunct for US Diagnosis of Biliary Atres (0 replies)
  32. Minimal access portoenterostomy: advantages and disadvantages of standard laparoscopi (0 replies)
  33. Radiofrequency (RF)-Assisted Hepatectomy May Induce Severe Postoperative Liver Damage (0 replies)
  34. Religious Views on Donation (0 replies)
  35. Herbal Medications and Liver Disease (0 replies)
  36. Drugs and Medications that Cause Liver Disease (0 replies)
  37. Pediatrics Newborn Screening Fact Sheet (2 replies)
  38. Babies Receive Recommended Newborn Screening Tests (0 replies)
  39. Vaccinations for Adult Solid-Organ Transplant Recipients Part 1 (0 replies)
  40. British scientists grow human liver in a laboratory (0 replies)
  41. ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Pati (0 replies)
  42. Liver Cancer Pill Extends Lives (0 replies)
  43. Alpha-1-Antitrypsin Deficiency: Current Concepts (0 replies)
  44. Effect of intraoperative hyperglycemia during liver transplantation (0 replies)
  45. Early hepatic artery thrombosis after liver transplantation: diagnosis and treatment (0 replies)
  46. Stem cells as a therapeutic modality in pediatric malformations (0 replies)
  47. Study: Liver Cancer Breakthrough Found (0 replies)
  48. Experience with choledochal cysts in infants (0 replies)
  49. Short hepatic vein reconstruction in biliary atresia patients with absent inferior ve (0 replies)
  50. Frequency of urinary tract infection in pediatric liver transplantation candidates (1 replies)
  51. Angiographic Findings in Biliary Atresia (0 replies)
  52. Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant t (0 replies)
  53. Non-alcoholic fatty liver disease and childhood obesity. (0 replies)
  54. Telbivudine: a new option for the treatment of chronic hepatitis B. (0 replies)
  55. Characterization of erythrovirus B19 genomes isolated in liver tissues from patients (0 replies)
  56. Seasonal Incidents in biliary atresia (2 replies)
  57. Duration of antimicrobial prophylaxis in patients undergoing hepatectomy: a prospecti (0 replies)
  58. Risk factors for and management of delayed intraperitoneal hemorrhage after pancreati (0 replies)
  59. Hepaticojejunostomy-Analysis of Risk Factors for Postoperative Bile Leaks and Surgica (0 replies)
  60. Urinary tract infection in non-hospitalized patients with cirrhosis and no symptoms o (0 replies)
  61. Vascular complications after orthotopic liver transplantation after neoadjuvant thera (0 replies)
  62. Biliary intraepithelial neoplasia: an international interobserver agreement study and (0 replies)
  63. Significance of C4d staining in ABO-identical/compatible liver transplantation (0 replies)
  64. NIDDK research article (0 replies)
  65. UNOS publications (1 replies)
  66. The Interactive Body (0 replies)
  67. Short hepatic vein reconstruction in biliary atresia patients with absent inferior ve (0 replies)
  68. Drug insight: the role of albumin in the management of chronic liver disease. (0 replies)
  69. Imaging findings in congenital hepatic fibrosis (1 replies)
  70. Whatever happened to "neonatal hepatitis"? (0 replies)
  71. Neonatal hemochromatosis: long-term experience with favorable outcome. (0 replies)
  72. Novel resequencing chip customized to diagnose mutations in patients with inherited s (0 replies)
  73. Safety of living-related liver transplantation for progressive familial intrahepatic (1 replies)
  74. Pulmonary vascular abnormalities in cirrhosis (0 replies)
  75. Intrahepatic cystic lesions after hepatic portoenterostomy for biliary atresia with b (0 replies)
  76. Pregnancy in biliary atresia after kasai operation complicated by portal hypertension (0 replies)
  77. Autoimmune hepatitis in children (0 replies)
  78. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences (0 replies)
  79. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysi (0 replies)
  80. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, (0 replies)
  81. Decreased protein C activation in patients with fulminant hepatic failure. (0 replies)
  82. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin defici (0 replies)
  83. Immunosuppressive therapy does not prevent the occurrence of immunoglobulin E-mediate (4 replies)
  84. Liver involvement in celiac disease (0 replies)
  85. Effect of living donor liver transplantation on outcome of children with inherited li (0 replies)
  86. Visual loss and idiopathic intracranial hypertension in children with Alagille syndro (0 replies)
  87. Types of Biliary Atresia (1 replies)
  88. Biliary atresia with choledochal cyst: implications for classification (0 replies)
  89. Liver transplantation at Red Cross War Memorial Children's Hospital. (0 replies)
  90. The model for end-stage liver disease score is useful for predicting economic outcome (0 replies)
  91. Prognostic value of portal pressure at the time of Kasai operation in patients with b (0 replies)
  92. Association of serum levels of tissue inhibitors of metalloproteinase-1 with clinical (0 replies)
  93. The role of monocyte chemoattractant protein-1 in biliary atresia (0 replies)
  94. Long-term outcome in type I biliary atresia. (0 replies)
  95. Successful liver transplantation across the ABO incompatibility barrier in 6 cases of (0 replies)
  96. Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report. (0 replies)
  97. Differential diagnosis of infantile choledochal cyst with or without biliary atresia (0 replies)
  98. BA in a Border Collie (3 replies)
  99. Types of Liver Diseases (0 replies)
  100. Unos (1 replies)